User contributions
From WikiPathways
(Latest | Earliest) View (newer 50) (older 50) (20 | 50 | 100 | 250 | 500)
- 15:43, 16 March 2025 Homo sapiens:Perturbed thyroid hormone homeostasis leading to developmental neurotoxicity (Added reference to main paper) (top)
- 21:47, 2 March 2025 Homo sapiens:Perturbed thyroid hormone homeostasis leading to developmental neurotoxicity (Ontology Term : 'oligodendrocyte' added !)
- 21:47, 2 March 2025 Homo sapiens:Perturbed thyroid hormone homeostasis leading to developmental neurotoxicity (Ontology Term : 'neuron' added !)
- 21:46, 2 March 2025 Homo sapiens:Perturbed thyroid hormone homeostasis leading to developmental neurotoxicity (Ontology Term : 'neurodevelopmental disorder pathway' added !)
- 21:45, 2 March 2025 Homo sapiens:Perturbed thyroid hormone homeostasis leading to developmental neurotoxicity (Ontology Term : 'DOID:1561' removed !)
- 21:45, 2 March 2025 Homo sapiens:Perturbed thyroid hormone homeostasis leading to developmental neurotoxicity (Ontology Term : 'cognitive disorder' added !)
- 21:44, 2 March 2025 Homo sapiens:Perturbed thyroid hormone homeostasis leading to developmental neurotoxicity (Modified description)
- 21:40, 2 March 2025 N Homo sapiens:Perturbed thyroid hormone homeostasis leading to developmental neurotoxicity (New pathway)
- 13:00, 6 November 2024 Homo sapiens:Cigarette smoke induced lung fibrosis (added literature references and visual cleanup)
- 12:33, 6 November 2024 Homo sapiens:Cigarette smoke induced lung fibrosis (added KE IDs)
- 12:26, 6 November 2024 Homo sapiens:Cigarette smoke induced lung fibrosis (Ontology Term : 'pulmonary fibrosis' added !)
- 12:04, 13 June 2024 Homo sapiens:Frustrated phagocytosis leading to malignant pleural mesothelioma (connected line and removed AO pathway)
- 12:39, 14 May 2024 Homo sapiens:Hallmark of cancer: metastasis and epithelial-to-mesenchymal transition (Ontology Term : 'cancer pathway' added !)
- 12:19, 14 May 2024 Homo sapiens:Hallmark of cancer: metastasis and epithelial-to-mesenchymal transition (Modified title)
- 13:41, 21 February 2024 Homo sapiens:Liver steatosis adverse outcome pathway (Reverted to version '11:25, 23 June 2021' by <a href="/index.php/User:Marvin_M2" title="User:Marvin M2">Marvin M2</a>)
- 13:39, 21 February 2024 Homo sapiens:Liver steatosis adverse outcome pathway (Reverted to version '11:25, 23 June 2021' by <a href="/index.php/User:Marvin_M2" title="User:Marvin M2">Marvin M2</a>)
- 13:38, 21 February 2024 Homo sapiens:Liver steatosis adverse outcome pathway
- 20:49, 15 February 2024 Homo sapiens:Mitochondrial complex inhibition leading to liver injury (Removed stressors)
- 20:29, 15 February 2024 Homo sapiens:Mitochondrial complex inhibition leading to liver injury
- 20:25, 15 February 2024 Homo sapiens:Arsenic liver toxicity pathway (Added reference)
- 21:23, 17 December 2023 Homo sapiens:Thyroid hormone imbalance leading to neurodevelopmental abnormalities (Modified description)
- 21:22, 17 December 2023 Homo sapiens:Thyroid hormone imbalance leading to neurodevelopmental abnormalities
- 21:18, 17 December 2023 Homo sapiens:Thyroid hormone imbalance leading to neurodevelopmental abnormalities (graphical updates)
- 14:34, 4 September 2023 Homo sapiens:Thyroid hormone imbalance leading to neurodevelopmental abnormalities (Updated layout, added chain of KEs)
- 09:14, 28 June 2023 Homo sapiens:DNA adduct formation leading to kidney failure (Ontology Term : 'kidney disease' added !)
- 09:08, 26 June 2023 Homo sapiens:Pleural mesothelioma (Modified description)
- 09:06, 26 June 2023 Homo sapiens:Pleural mesothelioma (Modified title)
- 13:47, 18 June 2023 N Homo sapiens:DNA adduct formation leading to kidney failure (New pathway)
- 13:33, 28 February 2023 Homo sapiens:ACE2 inhibition leads to pulmonary fibrosis (Replaced 2 Event notes with labels since these do not exist in AOP-Wiki)
- 13:28, 28 February 2023 Homo sapiens:ACE2 inhibition leads to pulmonary fibrosis (Added references)
- 13:25, 28 February 2023 Homo sapiens:ACE2 inhibition leads to pulmonary fibrosis (Ontology Term : 'CL:0000057' removed !)
- 13:23, 28 February 2023 Homo sapiens:Thyroid hormone imbalance leading to neurodevelopmental abnormalities (Added references)
- 13:19, 28 February 2023 Homo sapiens:Thyroid hormone imbalance leading to neurodevelopmental abnormalities (Ontology Term : 'thyroid hormone signaling pathway' added !)
- 13:09, 28 February 2023 Homo sapiens:Protein alkylation leading to liver fibrosis (created event nodes) (top)
- 13:07, 28 February 2023 Homo sapiens:Protein alkylation leading to liver fibrosis (added KE nodes)
- 12:50, 28 February 2023 Homo sapiens:Protein alkylation leading to liver fibrosis (Added tgf-beta pathway)
- 19:38, 13 December 2022 Homo sapiens:Thyroid hormone imbalance leading to neurodevelopmental abnormalities
- 19:36, 13 December 2022 Homo sapiens:Thyroid hormone imbalance leading to neurodevelopmental abnormalities (alignment changes)
- 12:58, 7 November 2022 Homo sapiens:Hormonal control of pubertal growth spurt (Label of somatostatin corrected) (top)
- 12:53, 7 November 2022 Homo sapiens:Hormonal control of pubertal growth spurt (Corrected GH and GHRH identifier annotation)
- 12:58, 4 November 2022 Homo sapiens:Focal adhesion: PI3K-Akt-mTOR-signaling (Typo corrected in label)
- 12:57, 4 November 2022 Homo sapiens:Hormonal control of pubertal growth spurt (Changed NCBI protein database to Entrez Gene)
- 12:18, 15 September 2022 Homo sapiens:Frustrated phagocytosis leading to malignant pleural mesothelioma (Modified title)
- 12:18, 15 September 2022 Homo sapiens:Frustrated phagocytosis leading to malignant pleural mesothelioma (Modified description)
- 12:15, 15 September 2022 Homo sapiens:Frustrated phagocytosis leading to malignant pleural mesothelioma (Added references)
- 05:46, 6 May 2022 AOP/Support (top)
- 05:42, 6 May 2022 AOP/Intro (→Welcome to the Adverse Outcome Pathway Portal!) (top)
- 05:41, 6 May 2022 AOP/Intro
- 14:50, 3 May 2022 Homo sapiens:Nephrotoxcicity adverse outcome pathway (created event node)
(Latest | Earliest) View (newer 50) (older 50) (20 | 50 | 100 | 250 | 500)
